Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock

Acrivon Therapeutics, Inc. Common Stock (ACRV) is a Healthcare stock trading at $1.57 (as of 2026-06-18), with a market capitalization of $64.63M and a trailing P/E of -0.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oncology therapies by using a proteomics-based approach to identify patients whose tumors are predicted to be sensitive to specific medicines. It applies this platform to create drug-specific companion diagnostics and is advancing ACR-368 in a Phase 2 trial, with additional preclinical programs targeting DNA damage response and cell-cycle regulation pathways.

Valuation — source: SEC EDGAR (first-party)
Price	$1.57
Market Cap	$64.63M
P/E Ratio	-0.8
EV / EBITDA	-0.4
Price / Book	0.70
DCF Value (model)	$-27.63
DCF Upside vs Price	-1859.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$7.00M
Net Margin	-862.7%
Return on Equity	-80.9%
Current Ratio	8.98

Valuation vs Sector & Industry
Stock P/E	-0.8
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-103.8%
vs Industry	-104.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($11.59M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Peter Blume-Jensen
Employees	75
Country	US
IPO Date	2022-11-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.